Car t-cell therapy for blood cancers that came back
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new car t-cell treatment for people with certain blood cancers that did not go away or came back after standard treatments. It aims to see if this therapy can help when other options have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 1 and 80 years old.
- You have a type of blood cancer like acute lymphoblastic leukemia or large b-cell lymphoma that is hard to treat.
- Your cancer cells show a marker called cd19, which the treatment targets.
- You have enough immune cells (cd3 count above 120 per microliter) for the therapy to work.
- You have not had car t-cell treatment before.
- You are generally well enough to participate, with a performance status score of at least 50%.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a one-time CAR T-cell treatment aimed at CD19, a target found on many B-cell leukemias and lymphomas. It’s for people whose disease has come back or hasn’t responded to prior treatments, or who can’t have a stem cell transplant.
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This trial tests a new CAR T-cell treatment for people with certain blood cancers (like some leukemias and lymphomas) that have not responded to other treatments. It may help even if previous CD19-targeted therapies have stopped working.
This study tests a personalized cell treatment called CAR-T for people whose blood cancer (like lymphoma, leukemia, or chronic lymphocytic leukemia) has come back or not gotten better after standard treatment. The therapy uses your own immune cells, modified in a lab, to find and fight the cancer.
This early-phase trial tests a special kind of immune cell treatment (CAR T cells) that targets CD20 and CD22 in people with relapsed or refractory B-cell cancers. It may help by attacking cancer cells that survived prior treatments, but it is still being studied for safety and early effectiveness.
Hear when a new B Cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.